Mohammed Nabil Nabil Quraishi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8300707/publications.pdf

Version: 2024-02-01

41 papers	3,201 citations	516215 16 h-index	360668 35 g-index
41 all docs	41 docs citations	41 times ranked	5703 citing authors

#	Article	IF	Citations
1	Insight from patients and healthcare professionals on the implementation of virtual clinics in patients with inflammatory bowel disease. Frontline Gastroenterology, 2022, 13, 104-110.	0.9	3
2	Prevalence of pouchitis in both ulcerative colitis and familial adenomatous polyposis: A systematic review and metaâ€analysis. Colorectal Disease, 2022, 24, 27-39.	0.7	11
3	The growth of faecal microbiota transplantation in the UK: time for a registry?. The Lancet Gastroenterology and Hepatology, 2022, 7, 112-114.	3.7	0
4	Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis. EBioMedicine, 2022, 81, 104088.	2.7	17
5	Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet?. Journal of Crohn's and Colitis, 2021, 15, 519-520.	0.6	1
6	COVID-19-related health anxieties and impact of specific interventions in patients with inflammatory bowel disease in the UK. Frontline Gastroenterology, 2021, 12, 200-206.	0.9	12
7	Breastfeeding promotes early neonatal regulatory Tâ€cell expansion and immune tolerance of nonâ€inherited maternal antigens. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2447-2460.	2.7	40
8	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.5	0
9	The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era. Lancet Microbe, The, 2021, 2, e133-e134.	3.4	5
10	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	3.7	23
11	The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterology, 2021, 12, 118-127.	0.9	16
12	COVID-19 vaccinations in patients with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 965-966.	3.7	12
13	Letter: faecal microbiota transplantation for IBS. Alimentary Pharmacology and Therapeutics, 2020, 52, 556-557.	1.9	8
14	Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVIDâ€19 in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2020, 52, 937-939.	1.9	2
15	An urgent need to institute COVID-19 testing in patients with IBD experiencing flares. Frontline Gastroenterology, 2020, 11, 330-331.	0.9	2
16	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	6.1	110
17	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. Journal of Crohn's and Colitis, 2020, 14, 935-947.	0.6	81
18	Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. The Lancet Gastroenterology and Hepatology, 2020, 5, 531.	3.7	29

#	Article	IF	Citations
19	Results from the first English stool bank using faecal microbiota transplant as a medicinal product for the treatment of Clostridioides difficile infection. EClinicalMedicine, 2020, 20, 100301.	3.2	16
20	Prevention of COVID-19 in patients with IBD. The Lancet Gastroenterology and Hepatology, 2020, 5, 639-640.	3.7	2
21	Development of a licenced Faecal Microbiota Transplantation service for the treatment of patients in the NHS. Access Microbiology, 2020, 2, .	0.2	0
22	Editorial: gut microbial profile associated with primary sclerosing cholangitisâ€"what is new and how do we progress from here?. Alimentary Pharmacology and Therapeutics, 2019, 50, 605-606.	1.9	2
23	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882225.	1.4	49
24	Do we really understand how faecal microbiota transplantation works?. EBioMedicine, 2019, 42, 39.	2.7	1
25	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989103.	1.4	15
26	Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045.	3.8	7
27	Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease. Clinical and Experimental Immunology, 2019, 199, 24-38.	1.1	40
28	STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis. BMJ Open, 2019, 9, e030659.	0.8	9
29	The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). Gastrointestinal Endoscopy, 2018, 88, 95-106.e2.	0.5	27
30	Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines. Journal of Hospital Infection, 2018, 100, 130-132.	1.4	14
31	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	1.4	38
32	The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	6.1	248
33	The gut-adherent microbiota of PSCâ€"IBD is distinct to that of IBD. Gut, 2017, 66, 386.1-388.	6.1	132
34	Systematic review with metaâ€analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology and Therapeutics, 2017, 46, 479-493.	1.9	455
35	Sa1049 The Virtual Electronic Chromoendoscopy (Vec) Score in Ulcerative Colitis Exhibits Very Good Inter-Rater Agreement in Scoring Mucosal and Vascular Changes After Computerised Module Training: A Study Across Academic and Community Practice. Gastrointestinal Endoscopy, 2017, 85, AB169-AB170.	0.5	0
36	National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK. Journal of Hospital Infection, 2017, 95, 444-445.	1.4	20

#	Article	IF	Citations
37	Faecal transplantation for IBD managementâ€"pitfalls and promises. British Medical Bulletin, 2017, 124, 1-10.	2.7	4
38	The gut microbiota and host health: a new clinical frontier. Gut, 2016, 65, 330-339.	6.1	1,719
39	182 Hemospray for Acute Upper Gastrointestinal Bleeding - UK 'Real-World' Single Center Experience. Gastrointestinal Endoscopy, 2015, 81, AB119.	0.5	0
40	Tu1254 Syringe Size Influences the Amount of Benzodiazepine Administered During Sedated Endoscopy. Gastrointestinal Endoscopy, 2013, 77, AB475.	0.5	0
41	Evaluation of gut bacterial populations using an electronic e-nose and field asymmetric ion mobility spectrometry: further insights into â€˜fermentonomicsâ€™. Journal of Medical Engineering and Technology, 2012, 36, 333-337.	0.8	31